8-K: Tivic Health Systems Regains Compliance with NASDAQ Minimum Bid Price Rule

Tivic Health Systems, Inc. has received confirmation from Nasdaq that it has regained compliance with the minimum bid requirements, allowing its common stock to continue trading on the Nasdaq Capital Market.

Summary

• Tivic Health Systems, Inc. announced that it has regained compliance with the Nasdaq minimum bid price requirement.
• The company received confirmation from Nasdaq on April 4, 2025, ensuring its continued listing on the Nasdaq Capital Market under the symbol TIVC.
• Previously, Tivic Health received a notification from Nasdaq on June 28, 2024, for not meeting the minimum bid price requirement of $1.00 per share.
• After a hearing, Nasdaq granted Tivic Health continued listing on March 6, 2025, contingent upon implementing a reverse stock split on March 7, 2025, and demonstrating compliance by March 20, 2025.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the company has overcome a significant hurdle by regaining compliance with Nasdaq listing requirements. However, the forward-looking statements disclaimer and inherent risks in the biotech industry temper the overall sentiment.

Positives

• Tivic Health has successfully regained compliance with Nasdaq's minimum bid price requirement, avoiding delisting.
• The company's stock will continue to be traded on the Nasdaq Capital Market, providing ongoing access to investors.
• The company has an FDA-approved over-the-counter device, ClearUP, for sinus pain and pressure.

Risks

• The press release includes a forward-looking statements disclaimer, indicating that actual results could differ materially due to various factors, including the company's financial condition.
• The company's continued listing on the Nasdaq Capital Market is subject to ongoing compliance requirements.

Future Outlook

The company's common stock will continue to be listed on the Nasdaq Capital Market. The company is developing non-invasive medical devices and has a biopharma division with a lead product candidate in late-stage studies.

Industry Context

Many small-cap companies face challenges in maintaining the minimum bid price required for listing on major exchanges like Nasdaq. Tivic Health's situation is not unique, and its successful remediation reflects positively on its management's ability to navigate regulatory hurdles.

Comparison to Industry Standards

• Many companies in the bioelectronic and biopharma industries face similar listing compliance challenges, especially during periods of market volatility or when clinical trials are ongoing.
• Compared to other companies that have failed to regain compliance, Tivic Health's successful implementation of a reverse stock split and subsequent compliance is a positive outcome.
• Other companies in similar situations include those developing novel therapeutics or medical devices that require significant capital investment and are subject to regulatory approvals.

Stakeholder Impact

• Shareholders will benefit from the continued listing of the company's stock on the Nasdaq Capital Market.
• Employees can be reassured that the company has addressed a critical compliance issue.
• Customers and partners can have confidence in the company's ongoing operations.

Key Dates

Keywords

Nasdaq, minimum bid price, compliance, listing, TIVC, Tivic Health Systems, reverse stock split